Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

335 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reduction of relapse rates by 18-month treatment in chronic hepatitis C. A Benelux randomized trial in 300 patients.
Brouwer JT, Nevens F, Bekkering FC, Bourgeois N, Van Vlierberghe H, Weegink CJ, Lefebvre V, Van Hattum J, Henrion J, Delwaide J, Hansen BE, Schalm SW; Benelux Study Group On Treatment Of Chronic Hepatitis C. Brouwer JT, et al. Among authors: van hattum j, van vlierberghe h. J Hepatol. 2004 Apr;40(4):689-95. doi: 10.1016/j.jhep.2003.12.017. J Hepatol. 2004. PMID: 15030987 Clinical Trial.
Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.
Orlent H, Desombere I, Hansen B, Van Vlierberghe H, Haagmans B, De Knegt RJ, Schalm SW, Leroux-Roels G, Janssen HL; DITTO-HCV Study Group. Orlent H, et al. Among authors: van vlierberghe h. Eur J Gastroenterol Hepatol. 2010 Dec;22(12):1443-8. doi: 10.1097/MEG.0b013e32833ef6e3. Eur J Gastroenterol Hepatol. 2010. PMID: 21389795 Clinical Trial.
Daily induction combination treatment with alpha 2b interferon and ribavirin or standard combination treatment in naive chronic hepatitis C patients. A multicentre randomized controlled trial.
Van Vlierberghe H, Leroux-Roels G, Adler M, Bourgeois N, Nevens F, Horsmans Y, Brouwer J, Colle I, Delwaide J, Brenard R, Bastens B, Henrion J, de Vries RA, de Galocsy C, Michielsen P, Robaeys G, Bruckers L. Van Vlierberghe H, et al. J Viral Hepat. 2003 Nov;10(6):460-6. doi: 10.1046/j.1365-2893.2003.00466.x. J Viral Hepat. 2003. PMID: 14633181 Clinical Trial.
Aminotransferases During Treatment Predict Long-Term Survival in Patients With Autoimmune Hepatitis Type 1: A Landmark Analysis.
Biewenga M, Verhelst X, Baven-Pronk M, Putter H, van den Berg A, Colle I, Schouten J, Sermon F, Van Steenkiste C, van Vlierberghe H, van der Meer A, van Hoek B; Dutch Autoimmune Hepatitis Study Group. Biewenga M, et al. Among authors: van steenkiste c, van vlierberghe h, van hoek b, van der meer a, van den berg a. Clin Gastroenterol Hepatol. 2022 Aug;20(8):1776-1783.e4. doi: 10.1016/j.cgh.2021.05.024. Epub 2021 May 20. Clin Gastroenterol Hepatol. 2022. PMID: 34022454 Free article.
Comparison of qualitative (COBAS AMPLICOR HCV 2.0 versus VERSANT HCV RNA) and quantitative (COBAS AMPLICOR HCV monitor 2.0 versus VERSANT HCV RNA 3.0) assays for hepatitis C virus (HCV) RNA detection and quantification: impact on diagnosis and treatment of HCV infections.
Desombere I, Van Vlierberghe H, Couvent S, Clinckspoor F, Leroux-Roels G. Desombere I, et al. Among authors: van vlierberghe h. J Clin Microbiol. 2005 Jun;43(6):2590-7. doi: 10.1128/JCM.43.6.2590-2597.2005. J Clin Microbiol. 2005. PMID: 15956369 Free PMC article.
Randomized placebo controlled phase I/II trial of alpha-galactosylceramide for the treatment of chronic hepatitis C.
Veldt BJ, van der Vliet HJ, von Blomberg BM, van Vlierberghe H, Gerken G, Nishi N, Hayashi K, Scheper RJ, de Knegt RJ, van den Eertwegh AJ, Janssen HL, van Nieuwkerk CM. Veldt BJ, et al. Among authors: van vlierberghe h, van der vliet hj, van den eertwegh aj, van nieuwkerk cm. J Hepatol. 2007 Sep;47(3):356-65. doi: 10.1016/j.jhep.2007.04.018. Epub 2007 Jun 6. J Hepatol. 2007. PMID: 17599630 Clinical Trial.
335 results